Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

A research team at the Medical University of Vienna led by Maria Sibilia has investigated a new combination therapy against cancer. This therapy ...

Researchers at MedUni Vienna have developed a combination therapy using systemic interferon-I and topical imiquimod.

Researchers believe the innovative idea holds immense promise for tackling a wide range of diseases including cancer through ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...

Ig-like receptors ILT3 and ILT4 can be activated ... was utilized in the production of this manuscript. Phenotype of dendritic cells (DCs) may determine the type of immune reaction generated ...

Thus, isolation-induced reduction in mechanosensation is determined before early adulthood, is PVD cell autonomous ... conditions and independently of the dendritic tree morphology. Thus, we used ...

This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for ...

This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and drives the activation and proliferation of ...